

Research Article / Araştırma Makalesi

The Impact of Age Over 80 Years on Outcomes in Geriatric Patients with Acute Pancreatitis: A Single Center Experience

Akut Pankreatitli Geriatrik Hastalarda 80 Yaş Üstü Olmanın Sonuçlar Üzerindeki Etkisi: Tek Merkez Deneyimi

<sup>1</sup>Hakan Şıvgın,<sup>2</sup>Abdurrahman Şahin

<sup>1</sup> Tokat Gaziosmanpaşa University Medical Faculty, Department of Internal Medicine, Tokat, Türkiye

<sup>2</sup>Tokat Gaziosmanpaşa University Medical Faculty, Department of Gastroenterology, Tokat, Türkiye

**Abstract:** The aim of this study is to evaluate the prognosis and mortality of acute pancreatitis (AP) in older subjects and compare octogenarians ( $\geq 80$  years) with nonoctogenarians (age  $< 80$  years). The medical records of elderly patients who were followed up with the diagnosis of AP at our clinic between January 2018 and December 2021 were retrospectively analyzed. The etiology of AP, comorbidities, laboratory parameters, intensive care unit (ICU) admission, and mortality were noted. Among survivors, one-year mortality status was also recorded. Disease severity, in-hospital mortality and one-year mortality were compared. A total of 206 older patients (60 octogenarian, 146 nonoctogenarian) were recruited to the study. Of them, 115 (56%) were female and the mean age was  $76.1 \pm 7.3$  years. Severity of AP didn't differ between octogenarians and nonoctogenarians ( $p > 0.05$ ). ICU admission was seen in 13% of octogenarians and 11% of nonoctogenarians ( $p > 0.05$ ). In-hospital mortality occurred in 8.3% of octogenarians and 6.8% of nonoctogenarians ( $p > 0.05$ ). After discharge, one-year mortality occurred in 20% of octogenarians and 6.6% of nonoctogenarians ( $p < 0.01$ ). In multivariate analysis severe AP (OR:24.940; %95CI:1.013–95.609;  $p = 0.01$ ), ICU admission (OR:10.244; %95CI:1.399–74.990;  $p = 0.01$ ) and chronic kidney disease (CKD) (OR:9.840; %95CI:1.013–95.609;  $p = 0.04$ ) were independent risk factors for in-hospital mortality, and  $\geq 80$  years (OR:2.984; %95 CI:1.116–7.980;  $p = 0.03$ ) and neurological disorders (OR:4.424; %95CI:1.480–13.226;  $p < 0.01$ ) were independent factors related to one-year mortality. Our results showed that advanced age has not a significant effect on the course of AP in elderly. Comorbidities play important role in short- and long-term outcomes in elderly. Larger prospective trials are needed to draw more definitive conclusions.

**Keywords:** Acute pancreatitis, Elderly, Mortality, Octogenarians, Severity

**Özet:** Bu çalışmanın amacı yaşlı bireylerde akut pankreatitin (AP) prognozunu ve mortalitesini değerlendirmek ve 80 yaş ve üzeri hastaları, 80 yaş altı hastalarla karşılaştırmaktır. Ocak 2018-Aralık 2021 tarihleri arasında kliniğimizde AP tanısı ile takip edilen yaşlı hastaların tıbbi kayıtları retrospektif olarak incelendi. Akut pankreatit nedeni, komorbiditeler, laboratuvar parametreleri, yoğun bakım ünitesine (YBÜ) yatış ve mortalite kaydedildi. Taburcu edilenlerde bir yıllık sağkalım durumu da kaydedildi. Akut pankreatit şiddeti, hastane mortalitesi ve bir yıllık mortalite karşılaştırıldı. Çalışmaya toplam 206 yaşlı hasta (60'ı 80 yaş üzeri, 146'sı 80 yaş altı) dahil edildi. Bunların 115'i (%56) kadındı ve yaş ortalaması  $76.1 \pm 7.3$  yıldı. AP şiddeti 80 yaş üzeri ve altı hastalar arasında farklılık göstermedi ( $p > 0.05$ ). YBÜ'nde yatış 80 yaş üzeri hastaların %13'ünde, 80 yaş altı hastaların %11'inde mevcuttu ( $p > 0.05$ ). Seksen yaş üzeri hastaların %8.3'ünde, 80 yaş altı hastaların %6.8'inde hastane mortalitesi meydana geldi ( $p > 0.05$ ). Yaşayan hastalarda, taburculuk sonrası bir yıllık mortalite 80 yaş üzeri olanların %20'sinde ve 80 yaş altı olanların %6.6'ında görüldü ( $p < 0.01$ ). Çok değişkenli analizde şiddetli AP (OR:24.940; %95CI:1.013–95.609;  $p = 0.01$ ), YBÜ yatışı (OR:10.244; %95CI:1.399–74.990;  $p = 0.01$ ) ve kronik böbrek hastalığı (KBH) (OR:9.840; %95CI:1.013–95.609;  $p = 0.04$ ) hastane mortalitesi için bağımsız risk faktörleriyken, 80 yaş üzeri olmak (OR: 2.984; %95 CI:1.116–7.980;  $p = 0.03$ ) ve nörolojik hastalıklar (OR:4.424; %95CI:1.480–13.226;  $p < 0.01$ ) bir yıllık mortaliteyle ilişkili bağımsız faktörlerdi. Sonuçlarımız ileri yaşın yaşlılarda AP seyri üzerinde belirgin bir etkisinin olmadığını gösterdi. Yaşlılarda, komorbiditeler kısa ve uzun dönem sonuçlarda önemli rol oynamaktadır. Daha kesin sonuçlara varmak için daha büyük prospektif çalışmalara ihtiyaç vardır.

**Anahtar Kelimeler:** Akut pankreatit, Yaşlılar, Mortalite, Seksen yaş üzeri, Hastalık şiddeti

ORCID ID of the authors: HŞ. [0000-0001-5008-6576](https://orcid.org/0000-0001-5008-6576), AŞ. [0000-0001-5477-9492](https://orcid.org/0000-0001-5477-9492)

Received 05.01.2024

Accepted 29.02.2024

Online published 06.03.2024

Correspondence: Hakan ŞIVGIN – Tokat Gaziosmanpaşa University Medical Faculty, Department of Internal Medicine, Tokat, Türkiye

e-mail : [sivginhakan@gmail.com](mailto:sivginhakan@gmail.com)

## **1. Introduction**

The improvement of living standards and health conditions in the last decades has led to gradual increase in elderly population all over the world as well as in Turkey. According to the current data from the Turkish Statistical Institute, the average life expectancy in Turkey is 74.8 years for men and 80.3 years for women (1). In many countries, including Turkey, the elderly or older is defined as having a chronological age of 65 years or older. Older adults constitute a heterogeneous population that shows differences in their physical and mental function, cognitive status, and social aspects (2). Individuals aged 80 years or older, which is named as octogenarians, constitute a group of people that requires more intensive care and follow-up.

Acute pancreatitis (AP) is identified as the acute inflammation of the pancreatic gland and, is one of the most common gastrointestinal emergencies with high mortality (3). While gallstones and alcohol represent the main causes of AP, no etiology is found in up to 30% of patients and AP is defined as idiopathic in this group (4). The clinical picture varies from self-limiting acute localized inflammation of pancreas to severe multi-organ failure. Disease severity and prognosis is predicted by the revised Atlanta Classification. The severity is graded as mild, moderately severe and severe according to the revised Atlanta Classification. Mortality rate varies from 5% in mild cases up to 30% in those patients with infected pancreatic necrosis (5).

With the ageing of the population, an increasing number of elderly patients have begun to experience acute disorders including AP (6). Acute pancreatitis presents with more severe course in elderly patients with longer hospital stay and higher rate of intensive care unit (ICU) admission (7). Diagnosing of AP is more difficult in older patients compared to younger adults. The symptoms usually occur later and, tend to be nonspecific during presentation. The intensity of pain may be lower. Mild increases in amylase may be related to other gastrointestinal disorders (8). In the course of disease, elderly patients

deteriorate more easily compared to younger ones. Furthermore, the high comorbidity rate in the elderly population may result in severe consequences in AP. Age is a component of several AP severity indices like Ranson's criteria, the Modified Glasgow Prognostic Score, the bedside index of severity in acute pancreatitis (BISAP) and, Acute Physiology and Chronic Health Evaluation (APACHE) II score (9). Though most studies have demonstrated a higher mortality rate in older patients, a more severe course without increased mortality was demonstrated in other studies (5). Hence, it is necessary to determine the outcomes and clinical traits of AP in this specific population and apply required medical and interventional treatment is crucial for them (3). In the current study we aimed to focus on the clinical course of AP, including severity of AP, ICU admission, in hospital mortality and one-year all-cause mortality, among elderly patients, especially in octogenarian ones.

## **2. Materials and Methods**

In this retrospective study, elderly patients with AP ( $\geq 65$  years-old), who were treated at Gastroenterology Clinic of Tokat Gaziosmanpasa University Hospital between January 2018 and December 2021, were enrolled. Elderly patients were classified as nonoctogenarians between 65-80 years of age and octogenarians over 80 years of age. The diagnosis was made based on the presence of at least two of the three features: characteristic abdominal pain consistent with AP, serum amylase or lipase values at least three times greater than the upper limit of normal value, and radiological findings consistent with AP. Among elderly patients with AP, patients who had insufficient clinical and follow-up data were excluded from the study. Patients with recurrent pancreatitis were enrolled only at first admission.

Demographic, clinical, and laboratory data were retrieved for assessment of disease severity and clinical outcomes. Age, gender, comorbid diseases including diabetes mellitus (DM), hypertension (HT), coronary heart disease (CHD), heart failure, chronic kidney

disease (CKD), neurological disorders and pulmonary disorders were recorded. Etiology of AP was determined as biliary or non-biliary. Laboratory parameters on admission and at the second day of admission were also recorded. Severity of AP was determined using the revised Atlanta Classification, and graded as mild, moderately severe and severe. Ranson's criteria scores and BISAP scores were also recorded. Ranson's score  $\geq 3$  and BISAP score  $\geq 3$  were accepted as severe AP. Data about length of hospitalization and ICU admission were obtained from hospital records. Outcomes included in-hospital AP related mortality and one-year all-cause mortality.

## 2.1. Statistical analysis

Statistical analysis was performed using SPSS v 20.0 (IBM, New York, USA). Continuous

variables were expressed as means and standard deviations or medians and standard error of mean. Categorical variables were expressed as frequencies and percentages. Student t test was used to compare normally distributed continuous variables and Mann-Whitney U test was used to compare non-normally distributed continuous variables. The chi-square test or Fisher's exact test was utilized for categorical variables. Logistic regression analysis was used for univariate and multivariate analyses to investigate factors associated with in-hospital mortality and one-year all-cause mortality. Variables with a significant p level ( $<0.05$ ) in univariate logistic regression analysis were used in the multivariate logistic analysis. Results were expressed as odds ratio (OR) with 95% confidence interval (CI). Values of  $p < 0.05$  were accepted as statistically significant in all comparisons.

## 2.2. Tables

**Table 1.** Demographic and clinical features of octogenarians and nonoctogenarians with acute pancreatitis

| Variable                          | Octogenarians<br>( $>80$ years) (n=60) | Nonoctogenarians<br>(65-80 years) (n=146) | p                             |
|-----------------------------------|----------------------------------------|-------------------------------------------|-------------------------------|
| Age (years)                       | 85 $\pm$ 5                             | 72 $\pm$ 5                                | <b><math>&lt;0.01</math></b>  |
| Gender, female n (%)              | 35 (58%)                               | 80 (55%)                                  | 0.64                          |
| Etiology, biliary n (%)           | 43 (72%)                               | 117 (80%)                                 | 0.19                          |
| <b>Comorbid illnesses, n (%)</b>  |                                        |                                           |                               |
| Diabetes Mellitus                 | 6 (10%)                                | 37 (25%)                                  | <b>0.01</b>                   |
| Hypertension                      | 37 (62%)                               | 93 (64%)                                  | 0.78                          |
| Coronary heart disease            | 18 (30%)                               | 37 (25%)                                  | 0.49                          |
| Heart failure                     | 13 (22%)                               | 17 (12%)                                  | 0.06                          |
| Mental and Neurological Disorders | 10 (17%)                               | 13 (9%)                                   | 0.11                          |
| Chronic kidney disease            | 3 (5%)                                 | 10 (7%)                                   | 0.76                          |
| Pulmonary Disorders               | 12 (20%)                               | 20 (14%)                                  | 0.26                          |
| <b>Severity</b>                   |                                        |                                           |                               |
| Revised Atlanta Class, n (%)      |                                        |                                           | 0.22                          |
| Mild                              | 22 (37%)                               | 69 (47%)                                  |                               |
| Moderately Severe                 | 30 (50%)                               | 54 (37%)                                  |                               |
| Severe                            | 8 (13%)                                | 23 (16%)                                  |                               |
| Ranson's score $\geq 3$ , n (%)   | 28 (47%)                               | 60 (41%)                                  | 0.46                          |
| BISAP score $\geq 3$ , n (%)      | 19 (31%)                               | 33 (23%)                                  | 0.17                          |
| ICU admission, n (%)              | 8 (13%)                                | 16 (11%)                                  | 0.63                          |
| Length of stay, median (25%-75%)  | 7 (5-9)                                | 6 (5-9.5)                                 | 0.59                          |
| In-hospital mortality, n (%)      | 5 (8.3%)                               | 10 (6.8%)                                 | 0.77                          |
| One-year mortality, n (%)         | 11/55 (20%)                            | 9/136 (6.6%)                              | <b><math>&lt; 0.01</math></b> |

BISAP, Bedside index of severity in acute pancreatitis; ICU, Intensive Care Unit.

**Table 2.** Laboratory parameters of octogenarians and nonoctogenarians with acute pancreatitis on admission and at second day of admission

| Variable                        | Octogenarians<br>( >80 years) (n=60) | Nonoctogenarians<br>(65-80 years) (n=146) | <i>p</i>        |
|---------------------------------|--------------------------------------|-------------------------------------------|-----------------|
| <b>On admission</b>             |                                      |                                           |                 |
| WBC ( $\times 10^6/L$ )         | 13100 $\pm$ 720                      | 13070 $\pm$ 410                           | 0.83            |
| Hemoglobin (g/dL) *             | 12.7 $\pm$ 2.1                       | 13.4 $\pm$ 1.9                            | <b>0.02</b>     |
| Hematocrit (%) *                | 38.0 $\pm$ 6.3                       | 39.9 $\pm$ 5.6                            | <b>0.03</b>     |
| Platelet ( $\times 10^9/L$ ) *  | 221 $\pm$ 76                         | 241 $\pm$ 85                              | 0.12            |
| ALT (U/L)                       | 147 $\pm$ 17                         | 228 $\pm$ 16                              | <b>&lt;0.01</b> |
| AST (U/L)                       | 239 $\pm$ 33                         | 280 $\pm$ 21                              | 0.07            |
| Calcium (mg/dL)*                | 9.1 $\pm$ 0.7                        | 9.2 $\pm$ 0.6                             | 0.35            |
| BUN (mg/dL)                     | 24 $\pm$ 1.6                         | 21 $\pm$ 0.8                              | 0.12            |
| Creatinine (mg/dL)              | 1.27 $\pm$ 0.16                      | 1.20 $\pm$ 0.08                           | 0.47            |
| Amylase (U/L)                   | 1430 $\pm$ 131                       | 1785 $\pm$ 96                             | <b>&lt;0.01</b> |
| Lipase (U/L)                    | 2295 $\pm$ 201                       | 2937 $\pm$ 230                            | 0.20            |
| CRP (mg/L)                      | 45.0 $\pm$ 9.0                       | 36.5 $\pm$ 3.8                            | 0.76            |
| <b>At 48 hours of admission</b> |                                      |                                           |                 |
| WBC ( $\times 10^6/L$ )         | 10835 $\pm$ 750                      | 10200 $\pm$ 425                           | 0.66            |
| Hemoglobin (g/dL)*              | 11.5 $\pm$ 2.0                       | 12.1 $\pm$ 1.7                            | <b>0.03</b>     |
| Hematocrit (%)*                 | 34.3 $\pm$ 5.9                       | 36.3 $\pm$ 5.0                            | <b>0.02</b>     |
| Platelet ( $\times 10^9/L$ )*   | 192 $\pm$ 70                         | 204 $\pm$ 73                              | 0.33            |
| ALT (U/L)                       | 124 $\pm$ 43.1                       | 138 $\pm$ 15.8                            | <b>&lt;0.01</b> |
| AST (U/L)                       | 115 $\pm$ 46.1                       | 102 $\pm$ 23.0                            | 0.37            |
| Calcium (mg/dL)*                | 8.6 $\pm$ 0.7                        | 8.7 $\pm$ 0.8                             | 0.72            |
| BUN (mg/dL)                     | 19 $\pm$ 1.5                         | 18 $\pm$ 1.2                              | 0.21            |
| Creatinine (mg/dL)              | 1.15 $\pm$ 0.12                      | 1.21 $\pm$ 0.10                           | 0.99            |
| CRP (mg/L)                      | 128.2 $\pm$ 11.8                     | 128.0 $\pm$ 8.2                           | 0.92            |

(\*) Mann–Whitney U test

ALT, Alanine aminotransferase; AST, Aspartate transaminase; BUN, Blood Urea Nitrogen; CRP, C reactive protein. WBC, White Blood Cell.

**Table 3.** Demographic and clinical factors associated with in-hospital mortality

| Variable                          | Dead (n=15)        | Alive (n=191)        | <i>p</i>         |
|-----------------------------------|--------------------|----------------------|------------------|
| <b>Age (years)</b>                | 75 $\pm$ 1.8       | 76.2 $\pm$ 7.3       | 0.77             |
| <b>Gender, female/ male n(%)</b>  | 5 (33%) / 10 (67%) | 110 (58%) / 81 (42%) | 0.10             |
| <b>Etiology, biliary n(%)</b>     | 11 (73%)           | 149 (78%)            | 0.75             |
| <b>Comorbid illnesses, n (%)</b>  |                    |                      |                  |
| Diabetes Mellitus                 | 3 (20%)            | 40 (21%)             | 0.93             |
| Hypertension                      | 10 (67%)           | 120 (63%)            | 0.76             |
| Coronary heart disease            | 5 (33%)            | 56 (26%)             | 0.55             |
| Heart failure                     | 3 (20%)            | 27 (14%)             | 0.46             |
| Mental and Neurological Disorders | 0 (0%)             | 23 (12%)             | <b>0.01</b>      |
| Chronic kidney disease            | 5 (33%)            | 8 (4%)               | <b>&lt; 0.01</b> |
| Pulmonary Disorders               | 3 (20%)            | 29 (15%)             | 0.70             |
| <b>Severity</b>                   |                    |                      |                  |
| Revised Atlanta Class, n (%)      |                    |                      | <b>&lt; 0.01</b> |
| Mild                              | 1 (7%)             | 90 (47%)             |                  |
| Moderately Severe                 | 2 (13%)            | 82 (43%)             |                  |
| Severe                            | 12 (80%)           | 19 (10%)             |                  |
| Ranson's score $\geq 3$ , n(%)    | 11 (73%)           | 77 (40%)             | <b>0.01</b>      |
| BISAP score $\geq 3$ , n(%)       | 13 (87%)           | 39 (20%)             | <b>&lt; 0.01</b> |
| <b>ICU admission, n (%)</b>       | 11 (73%)           | 13 (7%)              | <b>&lt; 0.01</b> |

BISAP, Bedside index of severity in acute pancreatitis; ICU, Intensive Care Unit.

**Table 4.** Multivariate logistic regression analysis for in-hospital mortality in acute pancreatitis

| Variable               | Univariate analysis |                  |             | Multivariate analysis |                 |             |
|------------------------|---------------------|------------------|-------------|-----------------------|-----------------|-------------|
|                        | OR                  | %95 CI           | p           | OR                    | %95 CI          | p           |
| Chronic kidney disease | 11.437              | 3.161 – 41.381   | < 0.01      | 9.840                 | 1.013 – 95.609  | <b>0.04</b> |
| Revised Atlanta, SAP   | 36.211              | 9.378 – 139.815  | < 0.01      | 24.940                | 1.860 – 334.330 | <b>0.01</b> |
| Ranson's score ≥3      | 4.071               | 1.251 – 13.254   | <b>0.02</b> | 0.167                 | 0.008 – 3.379   | 0.24        |
| BISAP score ≥3         | 25.333              | 5.487 – 116.059  | < 0.01      | 2.217                 | 0.150 – 32.725  | 0.56        |
| ICU admission          | 37.654              | 10.517 – 134.807 | < 0.01      | 10.244                | 1.399 – 74.990  | <b>0.02</b> |

BISAP, Bedside index of severity in acute pancreatitis; ICU, Intensive Care Unit; SAP, Severe acute pancreatitis.

**Table 5.** Demographic and clinical factors associated with one-year all-cause mortality among survivors from an acute pancreatitis event

| Variable                          | Dead (n=20) | Alive (n=171) | p           |
|-----------------------------------|-------------|---------------|-------------|
| Age (years)                       | 82±1.6      | 75.5±7.1      | <0.01       |
| Gender, female n (%)              | 12 (60%)    | 98 (57%)      | 1.00        |
| Etiology, biliary n (%)           | 13 (65%)    | 136 (80%)     | 0.16        |
| Comorbid illnesses, n (%)         |             |               |             |
| Diabetes Mellitus                 | 3 (15%)     | 37 (22%)      | 0.77        |
| Hypertension                      | 9 (45%)     | 111 (65%)     | 0.09        |
| Coronary heart disease            | 7 (35%)     | 43 (25%)      | 0.42        |
| Heart failure                     | 6 (30%)     | 21 (12%)      | <b>0.04</b> |
| Mental and Neurological Disorders | 7 (35%)     | 16 (9%)       | <0.01       |
| Chronic kidney disease            | 0 (0%)      | 8 (5%)        | 1.00        |
| Pulmonary Disorders               | 4 (20%)     | 25 (15%)      | 0.51        |
| Severity                          |             |               |             |
| Revised Atlanta Class, n (%)      |             |               | 0.63        |
| Mild                              | 3 (13%)     | 16 (9%)       |             |
| Moderately Severe                 | 7 (35%)     | 75 (44%)      |             |
| Severe                            | 10 (50%)    | 80 (47%)      |             |
| Ranson's score ≥3, n(%)           | 8 (40%)     | 69 (40%)      | 1.00        |
| BISAP score ≥3, n(%)              | 5 (25%)     | 34 (20%)      | 0.57        |
| ICU admission, n (%)              | 7 (35%)     | 16 (9%)       | <0.01       |

BISAP, Bedside index of severity in acute pancreatitis; ICU, Intensive Care Unit.

**Table 6.** Multivariate logistic regression analysis for all-cause one-year mortality among survivors from an acute pancreatitis event

| Variable                          | Univariate analysis |               |             | Multivariate analysis |                |             |
|-----------------------------------|---------------------|---------------|-------------|-----------------------|----------------|-------------|
|                                   | OR                  | %95 CI        | p           | OR                    | %95 CI         | p           |
| Age ≥ 80 years old                | 3.528               | 1.371 – 9.079 | < 0.01      | 2.984                 | 1.116 – 7.980  | <b>0.03</b> |
| Mental and Neurological Disorders | 5.216               | 1.820 – 4.954 | < 0.01      | 4.424                 | 1.480 – 13.226 | < 0.01      |
| Heart failure                     | 3.061               | 1.061 – 8.834 | <b>0.04</b> | 2.566                 | 0.836 – 7.876  | 0.10        |
| ICU admission                     | 1.616               | 0.332 – 7.874 | 0.55        | -                     | -              | -           |

ICU, Intensive Care Unit.

### 3. Results

Among 436 patients with diagnosis of AP, 206 of them were over 65 years old and included in the study. Octogenarian group consisted of 60 patients and 146 patients were in the nonoctogenarian group. One hundred and fifteen patients (56%) were female and the mean age was 76.1±7.3 years. The most

common cause of AP was gallstone related disorders in 72% of octogenarians and 80% of individuals under 80 years of age (p=0.19). While DM was less common in octogenarians (10% vs 25%, p=0.01), other comorbidities didn't differ between groups (for all, p>0.05) (Table 1).

Among laboratory parameters upon admission, hemoglobin ( $12.7 \pm 2.1$  g/dL vs  $13.4 \pm 1.9$  g/dL,  $p=0.02$ ), hematocrit ( $38.0 \pm 6.3$  vs  $39.9 \pm 5.6$ ,  $p=0.03$ ), ALT ( $147 \pm 17$  U/L vs  $228 \pm 16$  U/L,  $p < 0.01$ ) and amylase ( $1430 \pm 131$  U/L vs  $1785 \pm 96$  U/L,  $p < 0.01$ ) were lower in octogenarians. Similarly, hemoglobin ( $11.5 \pm 2.0$  g/dL vs  $12.1 \pm 1.7$  g/dL,  $p=0.03$ ), hematocrit ( $34.3 \pm 5.9$  vs  $36.3 \pm 5.0$ ,  $p=0.02$ ) and ALT ( $124 \pm 43.1$  U/L vs  $138 \pm 15.8$  U/L,  $p < 0.01$ ) were different between groups at 48 hours of admission. Other laboratory parameters didn't differ between groups (Table 2).

According to the revised Atlanta classification, there was no difference between octogenarians and nonoctogenarians ( $p=0.22$ ). Patients who had SAP consisted of 13% of patients over 80 years old and 16% of patients under 80 years old. Forty-seven percent of patients in octogenarian group and 41% of nonoctogenarians had a Ranson's score  $\geq 3$  ( $p=0.46$ ). Thirty-one percent of octogenarians and 23% of nonoctogenarians had a BISAP score  $\geq 3$  ( $p=0.17$ ). Eight patients (13%) of octogenarians and 16 patients (11%) of nonoctogenarians were admitted to ICU ( $p=0.63$ ). Five patients (8.3%) in octogenarian group and 10 patients (6.8%) in nonoctogenarian group died during hospitalization for AP ( $p=0.77$ ). After discharge of survivors, one-year mortality was 20% in octogenarian group and 6.6% in nonoctogenarian group ( $p<0.01$ ) (Table 1).

Death during hospitalization due to AP was seen in 7.3% of geriatric subjects. The median age was 75 years and two-thirds of them was male. While CKD was more common in mortal patients (33% vs 4%,  $p<0.01$ ), none of the patients who had neurological disorders died during hospitalization (Table 3). At the univariate analysis, a higher in-hospital mortality rate was associated with severe AP according to revised Atlanta classification (OR: 36.211; 95% CI: 9.378–139.815;  $p < 0.01$ ), Ranson's score  $\geq 3$  (OR: 4.071; 95% CI: 1.251–13.254;  $p=0.02$ ), BISAP score  $\geq 3$  (OR: 25.333; 95% CI: 5.487 – 116.059;  $p < 0.01$ ), ICU admission (OR: 37.654; 95% CI: 10.517–134.807;  $p < 0.01$ ) and CKD (OR: 11.437; 95% CI: 3.161–41.381;  $p < 0.01$ ) (Table 4). Multivariate analysis confirmed

that severe AP according to the revised Atlanta classification (OR: 24.940; 95% CI: 1.013–95.609;  $p=0.01$ ), ICU admission (OR: 10.244; 95% CI: 1.399–74.990;  $p=0.01$ ) and CKD (OR: 9.840; 95% CI: 1.013–95.609;  $p=0.04$ ) were independent risk factors for in-hospital mortality (Table 4).

Of the 191 patients who survived after the AP event, a total of 20 patients (10.5%) died within one year. Among them, 11 patients (20%) was in octogenarian group and 9 patients (6.6%) was in nonoctogenarian group. The median age of dead patients was 82 years (range 68–92) and 60% of them were female. The incidence of heart failure (30% vs 12%,  $p=0.01$ ) and neurological disorders (35% vs 9%,  $p < 0.01$ ) was higher among dead cases compared to living cases. One year mortality was not related to the severity of AP event, it was more common among patients who had admitted to ICU during hospitalization for AP (35% vs 9%,  $p < 0.01$ ). A comparison of demographic and clinical factors between dead and living patients after hospital discharge is presented in Table 5. In multivariate regression analysis, to be in octogenarian group (OR: 2.984; 95% CI: 1.116–7.980;  $p = 0.03$ ) and to have neurological disorders (OR: 4.424; 95% CI: 1.480–13.226;  $p < 0.01$ ) were independent factors related to one-year mortality (Table 6).

#### 4. Discussion

There is scarce data in the literature on the outcomes of AP in octogenarians and the impact of AP on the short- and long-term survival of octogenarians. In the present study we demonstrated that in-hospital mortality rate and AP severity were similar in octogenarians and younger ones. On the other hand, one-year mortality was higher in octogenarians and there was no impact of the AP severity on one-year mortality.

The major etiological factor was found as gallstones among our study population. A study from Europe reported an increased incidence of AP among patients aged over 65 years and, cholelithiasis was the main factor in elderly, especially in Mediterranean area (10). In a recent study from China, the main etiology was biliary in 88.6% of patients over

80 years old and, 79.6% of patients aged between 60-80 years old (3). Another study comparing octogenarian AP patients with AP patients aged between 65 and 80 years old from Türkiye showed that biliary etiology was responsible from 74.8% of octogenarians and 81.0% of nonoctogenarians (11). Mentioned study also showed that while neurological disorders were more common, DM was less common among octogenarian patients with AP. These findings were comparable with our results.

Acute pancreatitis is a common medical emergency, and older patients have unique features related to AP. Because their response to treatment may differ from young adults and, the presence of several comorbidities and frailty lead to vulnerability to organ failures and make treatment more difficult. It was demonstrated in a meta-analysis including 194,702 AP patients, a continuous, linear increase in the incidence of severe AP and mortality up to 60 years old with a rate of 0.193%/year and 0.086%/year, respectively (12). In the aforementioned study, while a rapid increase in mortality rate was found over 60 years old, severity of AP remained in linear slightly elevated pattern. The authors concluded that higher rate of comorbidities in geriatric population may explain the rapid increase in mortality. A national database study of 184,763 patients with biliary AP showed that 41% of cases were in the elderly group, and SAP and mortality showed an age-related increase in elderly cases, with higher rates in cases over 85 years of age (13).

Many studies have reported that higher mortality rate is evident in elderly (5, 6, 14). A recent multicenter study from Türkiye demonstrated a mortality rate of 1.6% in patients with AP (15). In our study, in-hospital mortality related to AP was 8.3% in octogenarians and 6.8% in nonoctogenarians. As expected, we had higher mortality rate in our elderly population. Di Mauro et al. found mortality rate among octogenarian patients with AP as 8% and, only 25% of deceased patients had biliary etiology (16). Similarly, Sahiner et al. found no difference in-hospital mortality between octogenarians (7.1%) and nonoctogenarians (6.5%) (11). On the contrary, Yu et al. showed that mortality

related to AP was 16.3% in patients over 80 years-old and 8.9% in patients between 60-80 years-old and, to be over 80 years old and organ failure were independent predictors of mortality in elderly AP patients(3).

Disease severity is the main predictor of poor outcome in AP. Several prognostic indices or classifications have been used to predict mortality and morbidity. As mentioned earlier, age is one of determinants in most indices. Of them, the most widely used are Ranson's criteria, BISAP and modified Atlanta classification. Several studies have reported higher Ranson's scores or BISAP scores in octogenarian patients compared to nonoctogenarians and younger adults (17, 18). In-hospital mortality related to AP is mostly because of organ dysfunction which involved in modified Atlanta classification. We demonstrated that severe AP according to the Atlanta classification was an independent predictor of death during AP event. On the other hand, Ranson's criteria and BISAP were unsatisfactory to predict mortality in multivariate analysis. Therefore, it is reasonable to prefer the revised Atlanta classification, which does not include an age component, in predicting disease severity in elderly.

Another predictor of in-hospital mortality was preexisting CKD. Acute kidney injury (AKI) is a serious complication of AP, with an incidence reaching up to 70% in patients with severe AP (19). Renal impairment and electrolyte disturbances significantly increases the risk of mortality, especially in patients who had preexisting CKD. Mortality was seen in one-third of patients who had CKD and only 4% of patients who had normal renal functions. Interestingly, none of AP patients with CKD died after hospital discharge. Instead, mortality rate was higher in patients who had heart failure and neurological disorders. Intensive care unit admission for AP event was also higher among dead patients that die after discharge. In multivariate analysis, age over 80, and neurological disorders were predictors of one-year mortality after discharge of an AP event. This may be explained by the fact that most patients who had preexisting neurological disorders or heart failure are monitored

closely in the ICU during the AP event. Moreover, in the current study it was demonstrated that one-year all cause mortality was not related with index AP event. Instead, it was closely related with age and neurological disorders. It is well known that mental and neurological disorders like stroke, Parkinson's disease or dementia are more common among older patients and, the mortality rate increases in these patients (20-22). Our one-year mortality results can be explained by this fact.

There are some limitations of the current study. First, because of the single-center retrospective feature of the study, potential biases could derive from the study design. All data were retrospectively collected, and hence, some data on demographic and clinical features might be missing and/or inaccurate. Due to single-center design, patient number might be insufficient to judge on predictive factors for mortality, and larger-scale

prospective studies are needed. We don't have a group of adult patients under 65 years old, so we couldn't compare geriatric patients with other adults. Therefore, our results cannot be generalized to all adult AP patients. Finally, we also don't have an octogenarian control group without AP for the assessment of factors causing long term mortality in octogenarians.

Consequently, we investigated demographic and clinical factors affecting severity of AP, AP related mortality and long-term mortality in the current study. Our results showed that to be over 80 years old doesn't influence clinical course of AP among older subjects. Furthermore, our analysis revealed that acute pancreatitis had no impact on long-term survival if treated appropriately. Comorbidities should be taken into account for poor short- and long-term outcomes in elderly.

## REFERENCES

1. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. *Nature Reviews Rheumatology* 2018; 14:107–119.
2. Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behçet's disease. *Intractable & Rare Diseases Research* 2015; 4:70–75.
3. Geri G, Wechsler B, Thi Huong D L, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. *Medicine* 2012; 91:25–34.
4. Kechida M, Salah S, Kahloun R, Klii R, Hammami S, Khohtali I. Cardiac and vascular complications of Behçet disease in the Tunisian context: clinical characteristics and predictive factors. *Advances in Rheumatology (London, England)* 2018; 58: 32.
5. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Annals of the Rheumatic Diseases* 2018; 77:808–818.
6. International Study Group for Behçet's Disease Criteria for diagnosis of Behçet's disease. *Lancet (London, England)* 1990; 335:1078–1080.
7. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *Journal of the European Academy of Dermatology and Venereology: JEADV* 2014; 28: 338–347.
8. Lakhanpal S, Tani K, Lie J. T, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. *Human Pathology* 1985;16: 790–795.
9. Mogulkoc N, Burgess M. I, Bishop P. W. Intracardiac thrombus in Behçet's disease: a systematic review. *Chest* 2000; 118: 479–487.
10. Yıldırım R, Oğuzman S, Dinler M, Bilge NŞY, Kaşifoğlu T. Scoping beyond pulmonary artery involvement; pulmonary involvement in Behçet's disease; a retrospective analysis of 28 patients. *Clin Rheumatol* 2023; 42:849-853
11. Bletry O, Mohattane A, Wechsler B, et al. Atteinte cardiaque de la maladie de Behçet. Douze observations [Cardiac involvement in Behçet's disease. 12 cases]. *Presse Medicale (Paris, France)* 1983, 1988;17: 2388–2391.
12. Gürgün C, Ercan E, Ceyhan C, et al. Cardiovascular involvement in Behçet's disease. *Japanese Heart Journal* 2002; 43: 389–398.
13. Emmungil H, Yaşar Bilge NŞ, Küçükşahin O, et al. A rare but serious manifestation of Behçet's disease: intracardiac thrombus in 22 patients. *Clinical and Experimental Rheumatology* 2014;32: S87–S92.

14. Aksu T, Tufekcioglu O. Intracardiac thrombus in Behçet's disease: four new cases and a comprehensive literature review. *Rheumatology International* 2015; 35: 1269–1279.
15. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. *Medicine* 2012; 91:35–48.
16. Erbilin E, Albayrak S, Gulcan E, et al. Acute coronary stenosis in a young man with Behçet's syndrome. *Medical principles and practice: international journal of the Kuwait University, Health Science Centre* 2008; 17: 157–160.
17. Calgüneri M, Aydemir K, Oztürk M A, Haznedaroğlu IC, Kiraz S, Ertenli I. Myocardial infarction and deep venous thrombosis in a young patient with Behçet disease. *Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis* 2006; 12: 105–109.
18. Güllü I H, Benekli M, Müderrisoğlu H, et al. Silent myocardial ischemia in Behçet's disease. *The Journal of Rheumatology* 1996; 23: 323–327.
19. Chen H, Zhang Y, Li C, et al. Coronary involvement in patients with Behçet's disease. *Clinical Rheumatology* 2019; 38: 2835–2841.
20. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. *Clinical Rheumatology* 2008; 27: 201–205.
21. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. *Arthritis and Rheumatism* 2012; 64: 2753–2760.
22. Assar S, Sadeghi B, Davatchi F, et al. The association of pathergy reaction and active clinical presentations of Behçet's disease. *Reumatologia*. 2017; 55: 79-83.
23. Gheita TA, El-Latif EA, El-Gazzar II, et al. Egyptian College of Rheumatology-Behçet's Disease Study Group (ECR-BDSG). Behçet's disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature. *Clin Rheumatol*. 2019; 38: 2565-2575.

#### Ethic

**Ethics Committee Approval:** The study was approved by Tokat Gaziosmanpasa University Interventional Clinical Research Ethical Committee (Decision no: 22-KAEK-073, Date: 31.03.2022).

**Informed Consent:** The authors declared that it was not considered necessary to get consent from the patients because the study was a retrospective data analysis.

**Authorship Contributions:** Authorship Contributions: Idea/concept: A.S. Design: H.A, A.S. Data Collection: H.A, A.S. Data Processing: H.A. Analysis/Comment: H.A, A.S. Literature research/review: H.A, A.S. Writing: A.S.

**Copyright Transfer Form:** Copyright Transfer Form was signed by all authors.

**Peer-review:** Internally peer-reviewed.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support